Molecular Pharmacology Program, Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Department of Medicine, Memorial Hospital, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Mol Cell. 2022 Jul 7;82(13):2443-2457.e7. doi: 10.1016/j.molcel.2022.04.034. Epub 2022 May 24.
RAF protein kinases are effectors of the GTP-bound form of small guanosine triphosphatase RAS and function by phosphorylating MEK. We showed here that the expression of ARAF activated RAS in a kinase-independent manner. Binding of ARAF to RAS displaced the GTPase-activating protein NF1 and antagonized NF1-mediated inhibition of RAS. This reduced ERK-dependent inhibition of RAS and increased RAS-GTP. By this mechanism, ARAF regulated the duration and consequences of RTK-induced RAS activation and supported the RAS output of RTK-dependent tumor cells. In human lung cancers with EGFR mutation, amplification of ARAF was associated with acquired resistance to EGFR inhibitors, which was overcome by combining EGFR inhibitors with an inhibitor of the protein tyrosine phosphatase SHP2 to enhance inhibition of nucleotide exchange and RAS activation.
RAF 蛋白激酶是小 GTP 酶 RAS 结合态 GTP 的效应物,通过磷酸化 MEK 发挥作用。我们在这里表明,ARAF 的表达以激酶非依赖性的方式激活 RAS。ARAF 与 RAS 的结合将 GTP 酶激活蛋白 NF1 置换,并拮抗 NF1 介导的 RAS 抑制。这降低了 ERK 依赖性的 RAS 抑制作用,增加了 RAS-GTP。通过这种机制,ARAF 调节了 RTK 诱导的 RAS 激活的持续时间和后果,并支持 RTK 依赖性肿瘤细胞的 RAS 输出。在具有 EGFR 突变的人类肺癌中,ARAF 的扩增与对 EGFR 抑制剂的获得性耐药有关,通过将 EGFR 抑制剂与蛋白酪氨酸磷酸酶 SHP2 的抑制剂联合使用,可以克服这种耐药性,从而增强核苷酸交换和 RAS 激活的抑制作用。